King Oyster Mushroom and Microbiome Diversity

King Oyster Mushroom

3 ranks of biological resolution across 5 studies — which is why they cannot be merged

Whole king oyster mushroom in obese mice increased four bacterial genera (Akkermansia, Lactobacillus, Bifidobacterium and Sutterella) and decreased five others. But the other king oyster microbiome studies report at family or phylum level, using different preparations in different disease models. The literature is more specific than most coverage admits, and less unified.

Du et al., Food Research International, 2024

Rikenellaceae

the only bacterial taxon named by two independent king oyster studies — increased by an isolated polysaccharide (Ma et al., 2017) and by a purified β-1,6-glucan (Wang et al., 2022)

Human tissue, not humans

the strongest translational study fermented king oyster with human fecal microbiota, then applied the supernatant to colonic biopsies from healthy donors. No participant ingested anything (Kerezoudi et al., 2025)

Zero clinical trials

no human trial has tested king oyster mushroom's effect on the gut microbiome, at any dose, for any duration

Du et al., Food Research International, 2024

View as image ↗

The story of mushrooms and the gut microbiome is usually told at a comfortable altitude: mushrooms contain polysaccharides, polysaccharides feed bacteria, bacteria produce short-chain fatty acids, and short-chain fatty acids are good for you. Every link in that chain is defensible. None of it tells you anything specific about king oyster mushroom.

The king oyster (Pleurotus eryngii) literature is more interesting than the generic version, and more awkward. Five separate studies have measured what this mushroom does to gut bacteria, and several of them name the organisms involved rather than gesturing at "beneficial bacteria." That specificity is real and it is worth reading.

What is not real is the tidy composite list that circulates in consumer coverage. Those five studies used different inputs — whole mushroom in some, an isolated polysaccharide in others, a single purified glucan in one — in different animal models, and they reported their results at three different levels of biological resolution — phylum, family and genus — while a fifth named no organism at all. A phylum is not a family and a family is not a genus. Stacking those findings into one bullet list of "bacteria king oyster grows" produces something that reads authoritatively and is not supported by any individual paper.

This article walks the five studies separately, names exactly what each one found, and marks clearly where the evidence stops. For broader context on the mushroom itself, see what is king trumpet mushroom: the meaty mushroom with health benefits, and for the adjacent mechanisms, king trumpet and short-chain fatty acid production and king oyster polysaccharides and immune modulation.

Why Microbiome Composition Matters

The gut microbiome is the community of microorganisms colonizing the large intestine, and it influences digestion, immune signalling, metabolic regulation and — through the gut-brain axis — aspects of neurological function. A microbiome with many species present in reasonable balance is broadly associated with better health outcomes across those domains.

Dysbiosis describes the opposite condition: depletion of certain populations, overgrowth of others, or a general collapse in species richness. The dysbiosis associated with high-fat diets and obesity is one of the better-characterized patterns in the field, and it is the backdrop for most of the king oyster research below, because researchers deliberately induce it in mice to have something to measure against.

One distinction matters more here than in most microbiome writing, because it is where the king oyster literature quietly diverges from itself.

The Ledger: What Each Study Actually Named

Before the individual studies, here is the whole picture in one place — the input each research group used, the model they used it in, and the exact taxa they reported.

Five Studies · Three Taxonomic Ranks · One Silence

What Each King Oyster Study Actually Named

These findings are frequently merged into one list of “bacteria king oyster grows.” They cannot be. The studies used different preparations, different disease models, and reported at different levels of biological resolution — phylum, family and genus are not interchangeable. Read each row on its own terms.

1. Ma and colleagues (2017)Family rankRef 1

   Input: Isolated polysaccharide (PEP, 426 kDa, 91.25% pure)·Model: Healthy mice, 6 weeks, 0.2–0.8 g/kg

   IncreasedPorphyromonadaceaeRikenellaceaeBacteroidaceaeLactobacillaceae

   Reported at family level only. The authors describe the work as exploratory, and the significant shifts were seen at the highest dose.

2. Hu and colleagues (2019)No taxa namedRef 2

   Input: Whole mushroom, 1% and 3% w/w of diet·Model: Mice, DSS-induced colitis

   Reports that whole P. eryngii significantly altered microbiota structure and partially reversed the DSS-induced shift — but names no specific taxon in the abstract.

3. Nakahara and colleagues (2020)Phylum rankRef 3

   Input: Hot-water polysaccharide fraction, 1% or 5% of diet·Model: C57BL/6J mice, high-fat diet, 16 weeks

   IncreasedFirmicutes (in BOTH high-fat and treated groups vs standard diet)

   The abstract states only that "some short-chain fatty acid-producing gut bacteria" were altered. No genus is named. Note the direction: Firmicutes rose in the treated group too — this is not a clean return to the standard-diet profile.

4. Wang and colleagues (2022)Family rankRef 4

   Input: Purified branched β-1,6-glucan (APEP-A-b)·Model: Mice

   IncreasedLachnospiraceaeRikenellaceae

   Also the only study here to pair the microbiota shift with a measured SCFA outcome in the same animals: acetic and butyric acid rose in cecum contents.

5. Du and colleagues (2024)Genus rankRef 5

   Input: Whole mushroom (WPE) in the diet·Model: Mice, high-fat-diet-induced obesity

   IncreasedAkkermansiaLactobacillusBifidobacteriumSutterella

   Decreasedrc4-4DoreaCoprococcusOscillospiraRuminococcus

   The most granular report in the set, and the only one using whole mushroom in an obesity model. The "decreased" list is worth reading carefully: Ruminococcus, Coprococcus and Dorea are not straightforwardly harmful organisms in every context.

Only one taxon appears in more than one study: Rikenellaceae, increased by both an isolated polysaccharide (Ma 2017) and a purified β-1,6-glucan (Wang 2022). That single overlap is the closest thing this literature has to independent replication of a named organism.

The pattern this makes visible is worth stating plainly. There is no consensus organism. There is one repeated taxon across two papers, several single-study findings at different ranks, and one study that names nothing at all. That is an early-stage literature, not a settled one.

Whole Mushroom in an Obesity Model: Du 2024

Du and colleagues took the approach most relevant to anyone who actually eats mushrooms: rather than isolating a polysaccharide, they fed whole king oyster mushroom to mice with high-fat-diet-induced obesity and measured both metabolic and microbiome outcomes.^[5]

The metabolic results were broad. Whole mushroom intake significantly inhibited abnormal body weight gain and adipose tissue weight, improved glucose tolerance, and improved serum biochemical parameters. Histological analysis showed that the severity of high-fat-diet-induced non-alcoholic fatty liver was significantly reduced. The mushroom also modulated the expression of hepatic genes involved in lipid metabolism, and raised short-chain fatty acid levels in the cecum — the direct signature of increased bacterial fermentation.

On the microbiome side, this is the only study in the set to report at genus level. Four genera increased: Akkermansia, Lactobacillus, Bifidobacterium and Sutterella. Five decreased: rc4-4, Dorea, Coprococcus, Oscillospira and Ruminococcus.

Akkermansia is the most interesting name on that list. Akkermansia muciniphila is a mucin-degrading organism that has become one of the most-studied bacteria in metabolic research, consistently associated with leaner phenotypes and better gut barrier function across many models. Its appearance here, in a whole-food intervention, is a genuinely notable result.

Most Granular Result

Du et al. (2024) · Food Research International

Population

Mice with high-fat-diet-induced obesity

Intervention

Dietary intake of whole Pleurotus eryngii mushroom (WPE)

Comparator

High-fat diet without mushroom

Finding

Significantly inhibited abnormal body weight and adipose tissue gain, improved glucose tolerance and serum biochemistry, and significantly reduced the severity of high-fat-diet-induced fatty liver. Cecal short-chain fatty acids increased. Gut microbiota analysis showed increased Akkermansia, Lactobacillus, Bifidobacterium and Sutterella, and decreased rc4-4, Dorea, Coprococcus, Oscillospira and Ruminococcus.

positive A mouse study, and the whole-food framing is the point — but note that the 'decreased' organisms are not uniformly harmful. Ruminococcus, Coprococcus and Dorea are common commensals, and in other contexts Coprococcus is treated as a beneficial butyrate producer. Reading the decrease list as 'harmful bacteria removed' oversimplifies what was measured.

Du et al., Food Research International, 2024; 184:114228

That caveat deserves emphasis rather than a footnote. The paper frames the decreased genera as "harmful," but several of them are ordinary members of a healthy human gut, and at least one is more often discussed as beneficial. What the study demonstrates is a shift, correlated with better metabolic outcomes in this specific model. It does not establish that each individual genus moved in a direction that would be desirable in a person.

What Nakahara 2020 Found — and What It Did Not

Nakahara and colleagues extracted soluble polysaccharides from king oyster with hot water and fed them to C57BL/6J mice for sixteen weeks, at either 1% or 5% of the diet, against a standard-diet control and an untreated high-fat control.^[3]

The metabolic findings were substantial and specific. In the high-dose group, body weight gain and mesenteric fat tissue were lower than in the untreated high-fat group. Serum total cholesterol and LDL cholesterol both decreased. Faecal lipid and total bile acid excretion increased, and the liver showed increased expression of the LDLR gene while fat tissue showed increased GPR43 — a receptor activated by short-chain fatty acids, which ties the metabolic result back to bacterial fermentation. The authors present this as the first evidence that king oyster polysaccharides have anti-obesity and LDL-lowering effects in obese mice.

That is a strong result. It is not, however, a microbiome-naming result, and this is where a widely circulated version of this article's topic goes wrong.

Reading The Literature Honestly

Did Nakahara 2020 name the bacteria king oyster feeds?

The claim

“Nakahara and colleagues identified specific genera promoted by king oyster polysaccharide — Allobaculum and Phascolarctobacterium — while suppressing Helicobacter.”

This genus-level list circulates widely in consumer coverage of king oyster and the microbiome, usually presented as the study's headline finding and offered as proof that the research is 'specific enough to name the organisms.'

What research shows

Unsupported

The published abstract reports the microbiome result at phylum level and in general terms: the relative abundance of Firmicutes was significantly higher in both the high-fat and treated groups than in the standard-diet group, and 'the abundance of some short-chain fatty acid-producing gut bacteria was altered by P. eryngii polysaccharides.' No genus is named. Allobaculum, Phascolarctobacterium and Helicobacter do not appear.

Those genera are real organisms with real literature behind them — Allobaculum and Phascolarctobacterium are both short-chain fatty acid producers associated with metabolic health in other studies. That plausibility is exactly what makes the misattribution durable: nothing about the claim sounds wrong. But a plausible organism attributed to a study that did not report it is still a fabricated citation, and the honest version of this section is that Nakahara's contribution is metabolic, not taxonomic.

Nakahara et al., European Journal of Nutrition, 2020; 59(7):3231-3244 (PMID 31865422)

There is a second detail in Nakahara worth sitting with, because it complicates the "reverses dysbiosis" framing that this topic attracts. Firmicutes was elevated in the treated group as well as the untreated high-fat group, relative to standard-diet controls. If king oyster polysaccharide were simply undoing high-fat-diet dysbiosis, you would expect the treated group to look more like the standard-diet group at the phylum level. It did not. The mushroom produced metabolic benefit alongside a microbiome that still looked high-fat-shaped at coarse resolution.

That is a more interesting finding than a clean reversal would be, and it is the kind of detail that disappears when studies get compressed into a takeaway.

The β-1,6-Glucan: Wang 2022

Wang and colleagues isolated a homogeneous branched β-1,6-glucan (designated APEP-A-b) from king oyster fruiting bodies — a structurally distinct polysaccharide from the β-1,3-glucans that dominate mushroom immunology research — and tested it in mice.^[4]

The immune results were measured as cell function rather than cytokine concentration. APEP-A-b significantly increased splenic lymphocyte proliferation, natural killer cell activity, and the phagocytic capacity of peritoneal cavity phagocytes. In the gut specifically, the proportion of CD4+ and CD8+ T cells in the lamina propria — the immune-cell-rich layer directly beneath the intestinal lining — significantly increased.

On the microbiome side, the glucan promoted the relative abundance of species in the Lachnospiraceae and Rikenellaceae families. Critically, the study also measured the metabolic output in the same animals: acetic acid and butyric acid concentrations both increased in cecum contents. That pairing matters. A shift in bacterial composition is a description; a shift in composition accompanied by a measured rise in the fermentation products those bacteria are supposed to make is a mechanism.

Structural Specificity

Wang et al. (2022) · Frontiers in Immunology

Population

Mice

Intervention

Homogeneous branched β-1,6-glucan (APEP-A-b) isolated from P. eryngii fruiting bodies

Comparator

Untreated controls

Finding

Significantly increased splenic lymphocyte proliferation, NK cell activity and phagocytic capacity of peritoneal cavity phagocytes. The proportion of CD4+ and CD8+ T cells in the lamina propria significantly increased. Relative abundance of Lachnospiraceae and Rikenellaceae rose, and acetic and butyric acid concentrations increased in cecum contents.

positive The authors' own conclusion is deliberately hedged — β-1,6-glucan 'might enhance immunity by modulating microbiota.' The study measured both effects in the same animals but did not establish that the microbiota shift caused the immune change; they are concurrent observations, and the causal arrow is proposed rather than demonstrated.

Wang et al., Frontiers in Immunology, 2022; 13:859923

The authors' hedge is worth preserving rather than smoothing over. "Might enhance immunity by modulating microbiota" is a hypothesis about mechanism, offered because both changes appeared together. The alternative — that the glucan acts on immune cells directly via receptors like dectin-1, and separately feeds certain bacteria — is equally consistent with the data.

Does Fermentation Actually Happen? Ma 2017

There is a prior question underneath all of this. A polysaccharide only functions as a prebiotic if gut bacteria actually ferment it. A molecule that reaches the colon and passes through unmetabolized has done nothing, however impressive its structure.

Ma and colleagues addressed that directly.^[1] They characterized a homogeneous king oyster polysaccharide (426 kDa, 91.25 ± 3.14% purity, mainly glucose with β-type glycosidic linkages) and administered it orally to mice at 0.2, 0.4 or 0.8 g per kg body weight for six weeks.

At the high dose, short-chain fatty acid concentration, pH value and moisture content of the cecum and colon contents were all significantly altered relative to control (P < 0.05). Those three measurements together are the signature of active fermentation: bacteria consuming substrate, producing acids, and changing the local chemistry. The fecal microbiota was structurally different from control, with Porphyromonadaceae, Rikenellaceae, Bacteroidaceae and Lactobacillaceae all increased at family level. Immune response was also significantly altered at the high dose.

Two qualifications belong with that result. First, the authors themselves label the work "exploratory" and frame the conclusion as king oyster polysaccharide having "a positive role in gastrointestinal tract health" — appropriately modest language for a first-pass characterization. Second, the effects concentrated at the highest dose, 0.8 g/kg body weight, which is a substantial exposure and not a straightforward analogue of eating mushrooms with dinner.

The appearance of Rikenellaceae here is the one genuine cross-study convergence in this literature. Two research groups, working with different preparations — a crude 426 kDa polysaccharide and a purified β-1,6-glucan — both reported it increasing. That is a weak signal by the standards of replication, but it is the only one available.

A follow-up from the same group in 2024 examined what happens to the fermentation products afterwards, characterizing how fermented king oyster polysaccharide interacts with the intestinal mucus layer.^[6] Fermented polysaccharide interacted with intestinal mucus in a way that reduced molecular aggregation: particle size at zero hours of fermentation measured 485.1 ± 11.3 nm with added mucus versus 989.33 ± 21.3 nm without it. This is physical chemistry rather than a health outcome, but it addresses a step the rest of the literature skips — what the fermentation products do once they reach the mucus layer where they would have to act.

Beyond Obesity: The Colitis Model

The obesity models dominate this topic, but one study tested king oyster against intestinal inflammation instead. Hu and colleagues fed whole king oyster mushroom at 1% and 3% of diet by weight to mice with dextran-sodium-sulfate-induced colitis.^[2]

Dietary king oyster alleviated colonic inflammation on three independent measures: decreased disease index, increased colon length (colon shortening is a standard readout of colitis severity), and reduced pro-inflammatory cytokines in the colonic mucosa. Sequencing showed that the mushroom significantly altered microbiota structure and partially reversed the shifts induced by DSS treatment. Cecal short-chain fatty acid levels increased.

The word "partially" is the study's own, and it is more informative than a stronger claim would be. The mushroom moved the microbiota back toward the pre-insult state without restoring it. The authors name no specific taxon in their abstract, which is why this study contributes a direction rather than an organism to the ledger above.

The Closest Thing to Human Evidence

Every finding to this point is from mice. One study used human material.

Kerezoudi and colleagues fermented king oyster mushroom with human fecal microbiota, producing a fermentation supernatant they designated FS-PEWS, then tested it against a bile-salt insult in two human systems: Caco-2 intestinal cell monolayers, and ex vivo colonic biopsies taken from healthy adult donors.^[7]

The Only Study Here That Used Human Tissue

What King Oyster’s Fermentation Products Did — and Did Not Do

Kerezoudi and colleagues fermented king oyster mushroom with human fecal microbiota, then applied the resulting supernatant to human intestinal cells and to colonic biopsies from healthy adult donors, against a bile-salt stressor. The selectivity of the result is the point: some markers recovered, others were untouched.

Read the input carefully. What was tested is not mushroom, and not a mushroom extract. It is the liquid left after human gut bacteria fermented the mushroom — the bacterial output, applied directly to tissue in a dish. No one ate anything in this study.

Tight junction proteinsCaco-2 human intestinal cell monolayer

• ZO-1Restored

  Downregulated by sodium deoxycholate; levels restored by the fermentation supernatant.

• Claudin-1Restored

  Downregulated by the stressor; levels restored, with cell viability maintained.

• OccludinNot reported restored

  Also downregulated by the stressor, but the abstract reports restoration only for ZO-1 and claudin-1. Two of three is the honest reading.

Permeability, in real human tissueEx vivo colonic biopsies, healthy adult donors

• Transcellular permeabilityRestored

  Selectively mitigated when the supernatant was combined with the stressor.

• Paracellular permeabilityNot reported restored

  Explicitly not affected. The protection is route-specific, not a blanket sealing of the barrier.

Inflammatory signallingCaco-2 and ex vivo colonic tissue

• TNF-αReduced

  Pro-inflammatory cytokine reduced by the fermentation supernatant.

• IL-6Reduced

  Pro-inflammatory cytokine reduced.

• IL-1βReduced

  Pro-inflammatory cytokine reduced.

• TLR-4 / dectin-1Modulated

  Receptor-mediated pathways modulated. Dectin-1 is the canonical β-glucan receptor, which is mechanistically consistent with a mushroom glucan being the substrate.

This is the closest king oyster research comes to human evidence, and it still stops well short of a clinical result. Cells and biopsies cannot tell you what happens when a person eats a mushroom — only that the machinery is capable of responding. Ref 7

The results are worth reading for their selectivity. Sodium deoxycholate downregulated three tight-junction proteins — ZO-1, occludin and claudin-1. FS-PEWS restored ZO-1 and claudin-1 while maintaining cell viability; occludin is not reported as restored. In the donor biopsies, the supernatant maintained tissue integrity and selectively mitigated transcellular permeability without affecting paracellular permeability. It reduced TNF-α, IL-6 and IL-1β, and modulated TLR-4 and dectin-1 signalling — dectin-1 being the canonical β-glucan receptor, which fits neatly with a mushroom glucan being the upstream substrate.

Two of three junction proteins, one of two permeability routes. That is a real and specific protective effect, and it is not the blanket "seals the gut barrier" that this kind of finding tends to become in summary.

The framing constraint is equally important: FS-PEWS is not mushroom. It is the liquid produced when human gut bacteria ferment mushroom, applied directly to tissue in a dish. The design is clever precisely because it isolates the bacterial output — but it means the study tells you the human gut can respond to king oyster's fermentation products, not that eating king oyster produces this effect in a living person.

Where The Evidence Actually Reaches

King Oyster & The Gut Microbiome

1. Cell and tissue studiescompleted

   Human Caco-2 monolayers and ex vivo colonic biopsies from healthy donors responded to king oyster fermentation supernatant with restored ZO-1 and claudin-1 and reduced TNF-α, IL-6 and IL-1β (Kerezoudi 2025).

2. Animal studiescurrent

   Five mouse studies across obesity and colitis models, using whole mushroom, crude polysaccharide and a purified β-1,6-glucan. Consistent direction on fermentation and short-chain fatty acids; inconsistent taxonomic resolution and no consensus organism (Ma 2017, Hu 2019, Nakahara 2020, Wang 2022, Du 2024).

3. Case reportsmissing

   None. No published clinical observations of king oyster affecting gut function in an individual.

4. Small human trialsmissing

   None. No pilot or open-label trial has measured king oyster's effect on human gut microbiota composition.

5. Large randomised trialsmissing

   None.

6. Meta-analysismissing

   Not possible — there are no human trials to pool.

King oyster's microbiome research is animal-stage, with a single human-tissue study at the base providing translational support. The mechanism is well characterized: the polysaccharides reach the colon, get fermented, and change both bacterial composition and short-chain fatty acid output. What has never been measured is whether eating king oyster mushrooms does any of this in a person.

Ma 2017; Hu 2019; Nakahara 2020; Wang 2022; Du 2024; Ma 2024; Kerezoudi 2025

Evidence Limitations

The gap between this literature and a practical claim is wider than the volume of research suggests, for four separate reasons.

Species translation. Mouse gut microbiomes differ substantially from human ones in composition, and several of the organisms named above behave differently in the two hosts. High-fat-diet mouse models are useful for isolating a metabolic mechanism, but they do not correspond to the range of human diets and metabolic states.

Preparation translation. Only two of the five in-body studies used whole mushroom. The others used a crude polysaccharide extract, a hot-water-soluble fraction at 1–5% of total diet, or a single purified glucan. A finding about a purified β-1,6-glucan does not automatically transfer to a mushroom you sauté, where that glucan is one component of a complex food matrix at a far lower concentration.

Dose translation. Ma's significant effects appeared at 0.8 g/kg body weight. Nakahara's high-dose group ate a diet that was 5% king oyster polysaccharide fraction by weight for sixteen weeks. Nobody eats this way.

Rank mismatch. As the ledger above shows, the studies do not report at comparable levels of biological resolution, which means they cannot be combined into a single account of which bacteria this mushroom feeds — even setting aside the differences in preparation and model.

Practical Context

Low

King oyster is a food, not a treatment for gut disease

Concern

The dysbiosis and colitis framing in this research can read as though king oyster mushroom were a therapeutic option for diagnosed gut conditions such as inflammatory bowel disease, irritable bowel syndrome or metabolic disease. It has never been tested that way in a human being.

What the research says

King oyster is a well-tolerated culinary mushroom with a long food history, and eating it carries no specific documented gut risk for most people. Treat it as a food with plausible prebiotic properties, not as an intervention. Anyone with an active inflammatory bowel condition, a known mushroom allergy, or a history of poor tolerance to fermentable fibers should raise dietary changes with their clinician first — fermentable polysaccharides can worsen symptoms in some people even when they are broadly beneficial at a population level.

Particularly relevant for: Anyone considering king oyster mushroom for a diagnosed digestive or metabolic condition

What to do

Do not substitute mushrooms for prescribed treatment of any gut condition. This article summarises preclinical research and is not medical advice; discuss any dietary change intended to affect a diagnosed condition with a qualified healthcare professional.

No human clinical trial of king oyster mushroom and gut microbiota exists as of this review

What the evidence does support is narrower and still worth knowing. King oyster contains polysaccharides that survive human digestion, reach the colon, and are genuinely fermented there — that much has been demonstrated directly rather than assumed. Fermentation raises short-chain fatty acid output, including butyrate. In mice, the resulting compositional shift travels alongside better metabolic and inflammatory outcomes across several independent models. And human intestinal tissue responds to the products of that fermentation with measurably improved barrier protein expression and lower inflammatory cytokines.

That is a coherent, mechanistically plausible case for king oyster as a prebiotic food. It is not a demonstrated health effect in people, and the distance between those two statements is where most coverage of this topic loses its footing.

The Bottom Line

King oyster mushroom (Pleurotus eryngii) alters gut microbiota composition across seven preclinical studies, but they cannot be merged into a single list of bacteria it promotes — they used different preparations in different models and reported at three different taxonomic ranks, with one study naming no organism at all. Ma et al. (2017) confirmed genuine colonic fermentation, with Porphyromonadaceae, Rikenellaceae, Bacteroidaceae and Lactobacillaceae increased at family level. Hu et al. (2019) found whole mushroom partially reversed colitis-induced microbiota shifts. Nakahara et al. (2020) demonstrated anti-obesity and LDL-lowering effects but named no genus, and found Firmicutes elevated in treated animals as well as untreated high-fat controls. Wang et al. (2022) showed a purified β-1,6-glucan raised Lachnospiraceae and Rikenellaceae alongside cecal acetic and butyric acid. Du et al. (2024) provided the only genus-level result: whole mushroom increased Akkermansia, Lactobacillus, Bifidobacterium and Sutterella while decreasing five other genera. Kerezoudi et al. (2025) supplied the sole human-tissue evidence, restoring two of three tight-junction proteins in donor colonic biopsies. Rikenellaceae is the only taxon named by two independent studies. No human clinical trial has tested king oyster's microbiome effects.

Frequently Asked Questions

Does king oyster mushroom increase gut bacteria diversity?

In animal studies, king oyster mushroom changes gut bacterial composition rather than reliably increasing overall diversity. The most granular result comes from Du and colleagues (2024), who found that whole king oyster mushroom in obese mice increased Akkermansia, Lactobacillus, Bifidobacterium and Sutterella while decreasing rc4-4, Dorea, Coprococcus, Oscillospira and Ruminococcus. Other studies report at family or phylum level rather than genus level, and Nakahara and colleagues (2020) found Firmicutes elevated in treated animals as well as untreated high-fat controls — not the pattern you would expect from a straightforward diversity restoration. No human trial has tested king oyster's effect on the microbiome.

What bacteria does king oyster mushroom feed?

The named organisms depend entirely on which study you read, because they report at different taxonomic levels. At genus level, Du et al. (2024) report Akkermansia, Lactobacillus, Bifidobacterium and Sutterella increasing in mice. At family level, Ma et al. (2017) report Porphyromonadaceae, Rikenellaceae, Bacteroidaceae and Lactobacillaceae increasing, and Wang et al. (2022) report Lachnospiraceae and Rikenellaceae increasing. Rikenellaceae is the only taxon named by two independent studies, which makes it the closest thing to a replicated finding here. All of these results are from mice, and a family-level finding and a genus-level finding are not equivalent statements.

How does Pleurotus eryngii change the microbiome?

Pleurotus eryngii polysaccharides resist human digestive enzymes, reach the colon intact, and are fermented there by resident gut bacteria. Ma and colleagues (2017) confirmed this directly: high-dose polysaccharide significantly changed short-chain fatty acid concentration, pH and moisture content in the cecum and colon of mice, alongside a structurally different fecal microbiota. Wang and colleagues (2022) found a purified β-1,6-glucan raised acetic and butyric acid in cecum contents. The mechanism is fermentation and its metabolic products — the mushroom feeds bacteria that carry the enzymes to break down its particular polysaccharides, and those bacteria grow relative to their neighbours.

Is there any human evidence for king oyster and gut health?

No human clinical trial has tested king oyster mushroom's effect on the gut microbiome. The closest evidence is Kerezoudi and colleagues (2025), who fermented king oyster with human fecal microbiota and applied the resulting supernatant to human Caco-2 intestinal cells and to colonic biopsies from healthy adult donors. Against a bile-salt insult, it restored ZO-1 and claudin-1 (but not occludin), selectively mitigated transcellular but not paracellular permeability, and reduced TNF-α, IL-6 and IL-1β. That is human tissue responding in a dish, not a person eating a mushroom — a meaningful translational step, but not a clinical result.

Can king oyster mushroom fix gut dysbiosis?

That claim runs ahead of the evidence. In mice, dietary king oyster partially reversed the microbiota shift caused by DSS-induced colitis (Hu et al., 2019) and shifted several genera in high-fat-diet obesity (Du et al., 2024). But Nakahara and colleagues (2020) found Firmicutes elevated in the treated group as well as the high-fat group relative to standard diet, which is not a clean return to a healthy profile. No human study has tested whether eating king oyster mushrooms corrects dysbiosis in people, and dysbiosis itself is a loosely defined term rather than a diagnosable condition with agreed criteria. This is not medical advice, and mushrooms are not a treatment for any diagnosed gut condition.

Sources & References

1. 1RTHM-00894·Ma, Gaoxing et al. (2017). “In vivo fermentation of a Pleurotus eryngii polysaccharide and its effects on fecal microbiota composition and immune response..” Food & function.Study breakdown →PubMed →↩
2. 2RTHM-00560·Hu, Qiuhui et al. (2019). “Dietary Intake of Pleurotus eryngii Ameliorated Dextran-Sodium-Sulfate-Induced Colitis in Mice..” Molecular nutrition & food research.Study breakdown →PubMed →↩
3. 3RTHM-00643·Nakahara, Daiki et al. (2020). “Effect of mushroom polysaccharides from Pleurotus eryngii on obesity and gut microbiota in mice fed a high-fat diet..” European journal of nutrition.Study breakdown →PubMed →↩
4. 4RTHM-00801·Wang, Xue et al. (2022). “β-1,6-Glucan From Pleurotus eryngii Modulates the Immunity and Gut Microbiota..” Frontiers in immunology.Study breakdown →PubMed →↩
5. 5RTHM-00876·Du, Hengjun et al. (2024). “Dietary intake of whole king oyster mushroom (Pleurotus eryngii) attenuated obesity via ameliorating lipid metabolism and alleviating gut microbiota dysbiosis..” Food research international (Ottawa.Study breakdown →PubMed →↩
6. 6RTHM-01943·Ma, Gaoxing et al. (2024). “Interactions between intestinal microbial fermentation products of Pleurotus eryngii polysaccharide with gut mucus..” Food & function.Study breakdown →PubMed →↩
7. 7RTHM-02104·Kerezoudi, Evangelia N et al. (2025). “Pleurotus eryngii Mushrooms Fermented with Human Fecal Microbiota Protect Intestinal Barrier Integrity: Immune Modulation and Signalling Pathways Counter Deoxycholic Acid-Induced Disruption in Healthy Colonic Tissue..” Nutrients.Study breakdown →PubMed →↩